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Abstract: 
Few chemotherapeutics have had such an impact on cancer management as cis-
diamminedichloridoplatinum(II) (CDDP), also known as cisplatin. The first member 
of the platinum based drug family, CDDP’s potent toxicity in disrupting DNA 
replication has led to its widespread use in multi-drug therapies, with particular 
benefit in patients with testicular cancers. However, CDDP also produces significant 
side effects that limit the maximum systemic dose. Various strategies have been 
developed to address this challenge including encapsulation within micro- or 
nanocarriers and the use of external stimuli such as ultrasound to promote uptake and 
release. The aim of this article is to look at these strategies and recent scientific and 
clinical developments. 
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Graphical Abstract: 
 
Alternative methods of delivery for cisplatin. (1) Cisplatin modifications reduce 
toxicity, enable binding to nanocarriers and provide sites of enzymatic or 
environmental action. (2) Nanocarrier encapsulation can reduce systemic toxicity and 
potentially improve retention at a tumor site by the enhanced permeability and 
retention (EPR) effect. (3) Tumor uptake of these nanocarriers can be further 
improved using external, physical force methods, for example a) magnetism, b) 
ultrasound and/or, c) heat. (4) Finally, these physical force methods, among others, 
can be used to trigger cisplatin release from nanocarriers to improve site specific 
delivery. 
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Vocabulary: 
Nanocarrier – a particulate agent capable of encapsulating or conjugating to a 
drug; for instance a liposome, polymer nanoparticle, micelle, etc., ranging in size 
from 1 nm to 500 nm. 
Liposome – a lipid bilayer coated particle with an internal aqueous volume. 
Polymeric nanoparticle – a polymer based particle that may be solid throughout or 
contain internal aqueous volumes, and can consist of multiple polymer components. 
Micelle – a self-assembling particle that can be formed of lipids, ionic surfactants 
or amphiphilic block copolymers. 
Enhanced permeability and retention (EPR) effect – an effect by which blood 
circulating nanocarriers extravasate into and are retained in the extracellular space in 
areas of the vasculature exhibiting abnormally large fenestrations between cells, such 
as in tumors. 
Cisplatin (CDDP) – the earliest of the platinum based antineoplastic family of 
chemotherapeutics, consisting of a cis-arrangement of chloride and amine irons 
around a platinum (II) core. 
Hyperthermia – an increase above the normal temperature range of the 
environment; in the human body ~37oC. For most tissues, sub-lethal temperatures 
below 45oC can be held for an extended duration with minimal cell death. Ablative 
hyperthermia above 60oC causes irreversible denaturation of proteins and cell death. 
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The discovery of cisplatin and subsequent expansion of the platinum based 
chemotherapy drug family has revolutionized the treatment of certain cancers, and 
these drugs now account for almost 50% of clinically used anticancer therapeutic 
agents.1 Initially discovered as an anti-bacterial agent over 50 years ago, cisplatin was 
found to have potent inhibitory effects on cancer.2 This led to its use against a wide 
range of tumors, including head and neck, cervical, bladder and ovarian.3 Of 
particular note is the use of cisplatin in testicular cancer. Its introduction to the 
combined drug therapy of disseminated germ cell tumors in testicular cancer raised 
the chemotherapy cure rate from 5% to approximately 80%.4 Cisplatin is now used in 
a variety of different drug combinations and forms the cornerstone for a number of 
chemotherapy treatments.5 
Despite its widespread clinical use, the side effects associated with the toxicity of 
cisplatin are significant and limit the maximum dose that can be administered.6 
Additionally, cisplatin resistance is a major concern for long term drug use. Thus, 
there has been great interest in developing strategies to reduce the systemic toxicity of 
cisplatin and improve the efficacy of cancer treatments.7 Much attention has been 
focused on creating drug delivery systems that can temporarily passivate platinum 
complexes such as cisplatin and enable transport to the tumor site. Candidate systems 
include liposomes, micelles, polymers and inorganic nanoparticles. For all untargeted 
nanocarrier systems, however, effective deposition in tumor tissue relies primarily 
upon the enhanced permeability and retention effect (EPR). This effect is highly 
dependent upon the characteristics of the tumor, which may cause limited and/or 
heterogeneous extravasation of nanoparticles in solid tumors.8,9 Consequently, more 
sophisticated “active” delivery strategies may need to be applied to improve tumor 
uptake. For example, it has been demonstrated that ultrasound can be used both to 
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target drug release from nanocarriers and enhance extravasation and distribution of 
chemotherapy agents in tumor tissue.10  
The following sections outline the mechanisms of action and limitations of cisplatin 
and other platinum chemotherapy agents, and review strategies for improving the 
therapeutic ratio by physical delivery of nanocarriers, with a focus on polymeric 
encapsulation of cisplatin and ultrasound mediated delivery. 
Mechanism of action of cisplatin 
Cisplatin’s structure and mechanism of action is shown in Figure 1. The most 
recognized mode of cytotoxic activity is the creation of unrepairable platinum-DNA 
adducts on purine bases, ultimately resulting in sufficient DNA damage to trigger 
apoptosis in the cell. Accumulation of cisplatin molecules within the cell is directly 
linked to their toxicity. It has been shown that the greater the number of DNA adducts 
of cisplatin, the greater the cytotoxic effects seen within the cell. Cisplatin initially 
enters the cell via both passive diffusion and active uptake, primarily through the 
copper membrane transporter CTR1.11 In the bloodstream, cisplatin is relatively stable 
and maintains its neutral state, due to the high concentration of chloride ions (~100 
mM). Once inside the cell, however, the relatively low chloride ion concentration (~4-
12 mM) causes cisplatin to undergo aquation, whereby a chloride is displaced by a 
water molecule.12 As shown in Figure 1 this is a key step as the aqua-cisplatin 
complexes do not readily diffuse from the cell, and importantly the mono-chloride 
form is a potent electrophile that will rapidly react with nucleophiles such as DNA. In 
DNA, this results in binding to the nitrogen in the N7 position on purine bases with 
loss of the water molecule.13 The remaining chloride is then subsequently aquated 
allowing the cisplatin to crosslink to another purine. Crosslinking between adjacent 
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guanine residues is considered to be crucial to the cytotoxicity of cisplatin.14 The 
adjuncts interfere with DNA replication and transcription causing cell cycle arrest and 
potentially activation of pro-apoptotic signals. Cell cycle arrest leads to activation of 
DNA repair pathways, particularly nucleotide excision repair (NER). The NER 
complex is capable of repairing DNA adducts of cisplatin by excising the damaged 
region and could allow for cell survival. However, should the DNA damage be too 
extensive to repair, apoptosis will be the likely outcome. 
 
Figure 1. Cisplatin structure and mechanism of action.  
 
DNA damage is not the only mechanism by which cisplatin may trigger apoptosis. 
Cisplatin’s interaction and reaction with other proteins has been linked to cellular 
damage. In particular, the induction of oxidative stress during cisplatin treatment can 
lead to mitochondria damage and dysfunction,15 glutathione depletion, lipid 
peroxidation, apoptotic pathway activation, and other deleterious effects. This 
combination of apoptotic effects results in a potent therapy against malignant solid 
tumors. 
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Limitations of cisplatin in chemotherapy  
The highly toxic nature of cisplatin is also its main drawback as a chemotherapy 
agent. Systemic administration of cisplatin produces severe side effects, ranging from 
hearing loss to hemolysis. The most significant dose-limiting side effect is 
nephrotoxicity, as cisplatin accumulates in the kidneys, which can cause unacceptable 
levels of renal failure at dosages over 120 mg/m2 body surface area.16 This process 
manifests itself in the destruction of nephron tubules, exacerbated by a loss of renal 
vasculature and the stimulation of a robust inflammatory response.17 Other common 
side effects in normal tissue include neurotoxicity and ototoxicity. Research has 
demonstrated that a combination treatment including antioxidants such as glutathione 
can reduce this damage without hampering therapy, however, the occurrence of these 
side effects requires a reduction of dosage and consequently a lowering of therapeutic 
effect. Other platinum containing drugs have also been developed that offer reduced 
side effects. For example, carboplatin has eliminated nephrotoxic effects but the 
reduced toxicity means a fourfold dose increase is required to match cisplatin’s 
efficacy. The relative ease of cisplatin modification has led to much focus on altering 
the structure to reduce the toxicity, with a particular focus on the platinum (IV) 
(Pt(IV)) prodrug. These inactive prodrugs can be reduced inside the cell by 
glutathione to active platinum (II), i.e. cisplatin. The additional binding sites formed 
on the platinum ion by this modification also provides a covalent attachment point for 
nanocarrier loading, construction of platinum cage forms18 or to other prodrugs, so 
called “dual threat” agents, such as histone deacetylase inhibitors.19-21 The research 
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into Pt(IV) prodrugs has been recently reviewed by Johnstone et al. and Kenny et al. 
22,23 
 
The other major concern associated with cisplatin is the relatively rapid 
development of resistance. There are multiple pathways by which a cell becomes 
resistant to cisplatin, but the key one appears to be a reduction in uptake. Whilst 
cisplatin is small enough to diffuse through cell membranes, its short half-life, both in 
terms of activity and elimination from the body, would not allow sufficient dose to 
enter cells. Instead, as previously mentioned, cisplatin is also taken up by active 
transport, primarily through CTR1. When stressed with cisplatin, cancer cells have 
been shown to reduce the expression of this transporter, necessitating an increasing 
dose of cisplatin for therapeutic effect.24 Additionally, cells may increase production 
of glutathione, which sequesters cisplatin,25 or increase DNA repair.26 Furthermore, in 
a clinical situation, it is often difficult to achieve a therapeutic concentration of drug 
throughout a solid tumor as a result of the tumor microenvironment.27 Cells which are 
far from a feeding vessel may receive a sub-lethal dose and become progressively 
more resistant with repeat dosing. To mitigate these factors, cisplatin is almost always 
given as a combination treatment, but cisplatin resistance remains a significant 
challenge. 
Cisplatin delivery using nanocarriers 
In order to address the aforementioned drawbacks of platinum containing drugs, 
much attention has been given to drug delivery strategies. One area of great interest in 
this field is encapsulation within nanoscale particles or “nanocarriers”. The 
complementary aims of this approach are first to reduce systemic toxicity by 
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temporarily passivating the drug during its transport through the blood stream and 
second to increase tumor uptake through targeting of the nanocarriers, thereby 
improving the therapeutic ratio (recently reviewed in depth in Johnstone et al.22). An 
ideal nanocarrier should thus encapsulate the drug with high efficiency, prevent 
premature degradation of the drug or interaction with healthy tissue and deliver its 
payload in a targeted and controlled manner. The simplest form of (passive) targeting 
exploits the differences between cancerous and healthy tissue to promote drug uptake 
in the tumor. Tumors typically feature “leaky” blood vessels and poor lymphatic 
drainage.28-30 Thus, whilst typical low molecular weight free chemotherapy agents 
will diffuse non-specifically through the walls of both healthy and tumor tissue, drugs 
loaded into nanocarriers can only extravasate in the highly permeable tumor capillary 
beds. The nanoscale dimensions of the carriers not only prevent their extravasation in 
normal tissues but also removal by renal clearance, making the size of delivery 
vectors very important. The cut-off size for extravasation into tumors has been 
reported as ∼400 nm during experiments with liposomes of different mean size,31 
however the consensus from different studies is that particles with diameters <200 nm 
are more effective.32  
Cisplatin and other platinum agents have been loaded into a variety of polymeric, 
lipid and inorganic nanocarriers, including liposomes, nanoparticles, and nanotubes. 
The most prominent attempts at reducing side effects have focused on liposomal 
encapsulation, which has been successfully utilized for encapsulation of another 
chemotherapy drug, doxorubicin. Doxorubicin is toxic to heart muscle, which can 
limit its usage for certain patients with pre-existing cardiomyopathies or in certain 
drug regimes, such as concurrent usage with Herceptin for breast cancer metastases. 
The two available liposomal encapsulated forms, Doxil (Johnson & Johnson, New 
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Brunswick, NJ, USA) or Myocet (Teva Pharmaceutical Industries, Petah Tikva, 
Israel), reduce the cardiotoxicity whilst maintaining therapeutic effect.  
However, utilizing the same liposome formulation for cisplatin, known as SPI-77 or 
Stealth® cisplatin, showed poor clinical results. Whilst accumulation of liposomes 
was demonstrated within tumors, the rate of cisplatin release was insufficient to 
produce a significant cytotoxic effect and clinical trials were halted.33,34 Recently, a 
fusogenic liposome formulation, Lipoplatin (Regulon Inc., Mountain View, CF, 
USA), has completed a number of phase II and phase III clinical trials on non-small 
cell lung carcinoma and pancreatic cancer. Like SPI-77, 10-50 times accumulation in 
tumors versus adjacent normal tissue was seen, but with a therapeutic effect similar to 
or greater than cisplatin only, typically when used in combination with paclitaxel.35 
Notably, Lipoplatin caused negligible toxicity.36 Several liposomal formulations of 
cisplatin or analogues have undergone clinical investigation, reviewed recently in Liu 
et al.
37 
Other incorporation techniques that have been used with platinum based drugs 
utilize different types of solid nanoparticles made of polymers (e.g., poly(lactic-co-
glycolic acid) (PLGA)), proteins (e.g., human serum albumin and right handed coiled 
coil38,39) or inorganics (e.g., silica NPs, gold NPs, iron oxide NPs, metal oxide 
frameworks, and carbon nanomaterials). Such nanoparticles utilize different strategies 
to load drugs. For example, PLGA particles consist of a permeable polymer mesh that 
provides sustained release of the encapsulated drugs. On the other hand, silica NPs 
have a high mesoporosity, with pores sizes from a few to tens of nanometers, and 
easily tunable surfaces which allows for a high loading capacity and slow release of 
drugs. Albumin based NPs have the advantage of albumin’s natural binding affinity to 
cisplatin, which reduces renal excretion and, despite the irreversible binding, appears 
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to retain cisplatin’s activity.40 There are several well-established techniques for 
producing loaded nanoparticles. These enable the properties of the nanoparticles, such 
as their size, shape, charge and permeability to be carefully tailored to the specific 
requirements of the application and the drug in question.  
Whilst promising, and potentially capable of numerous chemical modifications for 
targeting or release purposes, only two particle-based cisplatin agents have undergone 
clinical trials to date. Whilst not strictly a nanoparticle, BP-C1 (Meabco A/S., 
Copenhagen, Denmark) a benzene-poly-carboxylic acid complexed with cisplatin, 
recently completed a phase I and II trial for stage IV metastatic breast cancer versus a 
placebo. It was found that BP-C1 controlled tumor growth, had low toxicity and mild 
side effects, and improved quality of life.41 A 100 nm PEGylated, micellar 
nanoparticle, NC-6004 or Nanoplatin™ (Nanocarrier Co. Ltd., Kashiwa, Chiba, 
Japan), consisting of cisplatin bound to hydrophobic polymers is currently under 
clinical trial investigation for pancreatic (phase III), head and neck (phase I) and other 
solid tumors (phase II). Dose escalation studies have shown good tolerance of the 
NC-6004 with mild adverse events and some evidence of disease stabilization42 with 
reduced kidney damage in comparison to cisplatin treatments from a different study.43  
These cisplatin nanocarriers are important in demonstrating reduced toxicity and 
adverse events, concurrent with accumulation in tumors. However, whilst the 
reduction in toxicity is of enormous benefit to a patient’s quality of life, the 
comparable efficacy to free cisplatin indicates that further strategies are required to 
increase uptake and release from these nanocarriers to improve the clinical outcome. 
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Solid tumor barriers to passive delivery 
Passive delivery of untargeted nanocarrier systemic therapeutics to a therapy-
resistant solid tumor, is complicated by the pathophysiology of its microenvironment. 
Effective delivery via the EPR effect is complicated by a poorly organized and 
tortuous blood supply within a tumor. Whilst the leaky, ill-formed endothelial layer 
allows the extravasation of nanocarrier drugs, the abnormal flow conditions hinder 
their delivery to the tumor site.28-30 Additionally, the interstitial pressures of tumors is 
high, due to the rapid proliferation of cells in a tight area, vascular leakiness, and lack 
of development of lymphatic drainage, which further disrupts blood flow by 
squeezing vessels and preventing the pressure gradient-driven diffusion of large 
molecules out of the circulation.27,44 The rapid proliferation of cells and poor 
vasculature lead to regions of cells far removed from the circulation, increasing the 
diffusion distance required for therapeutics and inducing a treatment resistant hypoxic 
nature.45 Tumors can also exhibit a poorly organized extracellular matrix (ECM) high 
in collagen and charged glycosaminoglycans which obstructs tumor interstitial flow 
and prevent the penetration of large molecules deep into the tumor.46,47 These barriers 
to nanoparticle delivery have been previously reviewed in detail elsewhere.48,49 
With these barriers to delivery and the heterogeneity of tumors, any evidence for 
EPR effect requires careful consideration.50 In some cases, it has been estimated that 
EPR may only increase uptake in tumors two-fold in comparison to other organs and 
will depend highly on the tumor type, location and vascularity of the tumor.51 As 
such, nanoparticle delivery to target sites can be hindered by a lack of extravasation 
and/or retention ability in the most commonly used, unmodified vectors.52 
Additionally, the highly disorganized nature of tumor tissue and blood vessels can 
lead to non-uniform distributions of nanoparticles. Alternative strategies are therefore 
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required to improve drug uptake and drug release in a tumor. The following sections 
will detail the different methods that have been explored to improve delivery of 
cisplatin. 
Methods of Delivery 
Nanoparticle design 
The simplest approach to increasing uptake in tumors is to vary the physical 
parameters of the nanoparticle (recently reviewed by Blanco et al.53 and Durymanov 
et al.
54). As mentioned earlier, size, shape and charge55 can all play an important role 
in the extravasation of nanoparticles. These parameters also affect the clearance route 
and lifetime of the nanoparticle in circulation. For example, nanoparticles below 5 nm 
have excellent penetration and distribution within tumors but are rapidly cleared via 
the kidneys. Additionally, lowering the size of nanoparticles may compromise loading 
efficiency.56 For spherical particles, a twofold reduction in nanoparticle radius lowers 
the maximum loading volume eightfold, but also increases the specific surface area, 
which can affect release rate and interactions. As such, the most appropriate 
nanoparticle design will depend upon its specific application.  
 
Active targeting 
One method is to provide active targeting to tumor tissues by identifying distinct 
biomarkers. Tumor cells and surrounding healthy cells typically display an abnormal 
set of membrane bound receptors and proteins. Antibodies raised against these targets 
can be attached to nanocarriers to assist accumulation at the tumor site.57 Examples of 
such receptors include vascular endothelial growth factor receptor, VEGFR, which is 
expressed by the endothelial cells of growing blood vessels, as typically found in 
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nutrient starved solid tumors. Other receptors, such as folate receptor, biotin receptor, 
HER2, EGFR and interleukin-4, can all act as targets for antibody, peptide or small 
molecule targeting.58-60  
This form of targeting is relatively simple to achieve with surface modification of 
the nanoparticle (reviewed in61 and has formed part of a number of targeted cisplatin 
nanoparticles strategies.57, 62-64 However, there are some important considerations: 
First, for this type of targeting to be effective, the nanoparticles must come into 
sufficiently close proximity to the relevant cells. As previously mentioned, the EPR 
effect may only improve nanoparticle extravasation in a tumor site by twofold 
compared to normal organs, meaning that the majority of nanoparticles will rarely 
come into close contact with tumor cells. Thus, whilst those nanoparticles that enter 
the intracellular space may be better retained in the tumor, active targeting may not 
significantly improve uptake in large solid tumors with poor vascularization. Second, 
some targeting markers, particularly endothelial markers and others such as folate, 
can lead to rapid clearance65 and third, these markers may also be strongly expressed 
off-target.66 
 
Direct injection 
Several physical methods have also been proposed to increase local delivery and 
retention. The simplest method is to directly insert the drugs into the tumor tissue.  
Intraoperative approaches for debulking or eliminating residual tumor tissue include 
the insertion of chemotherapy drug pellets or wafers directly at the target site.67,68 An 
internal radiotherapy, or brachytherapy, works by a similar method and is typically 
performed in surgically challenging locations. For nanoparticles, intratumoral 
injection has been investigated as a way to ensure complete drug delivery in the target 
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site without dilution or loss in the circulation.69-71 Direct injection can also improve 
the distribution of the drug within the tumor.56, 71 However, intratumoral injections are 
not commonly used in clinical practice because of the invasiveness of the technique 
for deep tumor sites and the established nature of standard surgical or radiotherapy 
techniques for accessible tumor sites. Historically, investigations into direct injection 
of free drugs demonstrated rapid clearance, poor drug distribution and toxicity to 
surrounding tissue.72,73 
 
Tissue hyperthermia 
Tissue hyperthermia is a simple technique that can have a range of effects on a 
tumor’s microenvironment. Fluid flow around the tumor is improved, resulting in a 
reduction in interstitial pressure and improved chemotherapy drug uptake and effect,74 
along with a notable synergistic effect for cisplatin due to cellular changes.75,76 
Heating of cell membranes also increases lipid fluidity and permeability to drugs.77 
Finally, heating increases the diffusion rate of drugs, and can reduce hypoxia, a major 
barrier to effective drug delivery.78,79 There are many methods to apply heating to a 
target region, both invasively and non-invasively, and hyperthermia has been 
attempted with several different nanoparticles formulations.80,81 Indeed, the effect of 
hyperthermia in tumors can have further useful effects for the delivery of 
nanoparticles. Li et al. demonstrated that local, sub-lethal hyperthermia in a 
windowed, subcutaneous tumor model could induce gaps in the endothelial layer of 
up to 10 µm, with the vasculature still permeable up to 8 hours.82 This led to an 
increase in the accumulation and retention of 85 nm, fluorescently labelled liposomes, 
as shown in Figure 2.  
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However, as hyperthermia is a relatively non-specific delivery technique, heating 
must be localized to the target area to ensure effective target site delivery and reduce 
the effect on surrounding tissue. Heat transfer is subject to tissue and tumor 
heterogeneity, as well as cooling from blood flow. For instance, heating near bone can 
be particularly problematic due to the relatively low thermal conductivity of ossified 
tissue in comparison to soft tissue, which can lead to unintentional thermal necrosis or 
off-site delivery.83,84 The difficulty in assessing heat transfer impacts the treatment 
planning. Temperature monitoring can be performed, but this requires either 
implanting temperature probes, an invasive procedure which provides only single 
point information, or thermometry by magnetic resonance imaging (MRI), a costly 
procedure which limits the materials that can be used.85,86  
Whilst tissue hyperthermia does increase nanoparticle delivery, it is typically 
applied in combination with a nanoparticle modification aimed at triggering drug 
release under hyperthermic conditions as discussed later in the section on thermal 
release. 
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Figure 2. Accumulation of fluorescently labelled liposomes (TSL-IRDye 800CW) 
in a hind-limb subcutaneous tumor mouse model. a) Whole body imaging shows 
significant fluorescent signal from tumors four hours after liposome injection, when 
preceded by one hour of sub-lethal hyperthermia (HT) in the tumor bearing limb in 
comparison to normothermia (NT). Absolute tumor fluorescence peaked at 4 hours 
for hyperthermia treated mice but b) the tumor-to-background ratio (TBR) continued 
to increase as liposomes were cleared from blood circulation but retained in the 
tumor. Reprinted from Reference 82. Copyright (2013) with permission from 
Elsevier. 
 
Magnetic targeting 
Magnetic targeting has also become an attractive approach for cisplatin based drug 
delivery with the increasing availability of biocompatible superparamagnetic 
nanoparticles. Their ability to enhance MRI contrast to allow imaging,87-90 to localize 
in specific regions under external magnetic fields,91-94 and to cause local hyperthermia 
under oscillatory magnetic fields (discussed in the section on thermal release),95-97, 
makes them popular agents to include in drug formulations. Superparamagnetic iron 
oxide nanoparticles (SPION), are commonly used to add a magnetic response to 
larger nanoparticles or other vector particles, but require stabilization to prevent 
aggregation, oxidation and loss of magnetic properties. 
Cisplatin has been loaded extensively into solid and lipid based magnetic 
nanoparticles.94, 98-101 In one such study, Wagstaff et al. prepared 60 nm to 120 nm 
cisplatin loaded gold-coated iron-oxide nanoparticles for use against cisplatin 
sensitive and resistant cell lines.102 The conjugation of chemotherapy drugs on to gold 
nanoparticles has been shown to enhance uptake and cytotoxic effect, particular for 
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cisplatin and other platinum based chemotherapy drugs.103-106 The gold nanoparticle 
also stabilizes the iron oxide, preserving magnetic response. Gold was coated onto an 
iron oxide core and hydrated cisplatin conjugated to the gold via polyethylene glycol 
linkers (See Figure 3). The combination of the gold and cisplatin resulted in 
nanoparticles with over 100-fold improvement in the half maximal inhibitory 
concentration (IC50) values in cisplatin-sensitive cell lines. Inhibition of proliferation 
was also seen in specific regions when combined with a magnet. However, the 
unloaded gold-iron oxide nanoparticle itself displayed potent cytotoxicity and 
cisplatin resistance in a resistant cell line was not overcome with the loaded particle. 
Additionally, cisplatin release from the nanoparticle was not directly demonstrated 
and the strong coordinate bonds used to tether cisplatin to the nanoparticle to prevent 
systemic release, may prevent target site release and likely interfere with its mode of 
action.  
(1)  
(2)  (3) 
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Figure 3. A potential nanoparticle design combining the improved cytotoxicity of 
cisplatin and gold nanoparticles, with an ability to magnetically target to a location. 
(1) Schematic showing the final cisplatin bound, PEGylated gold-coated iron oxide 
nanoparticle. The nanoparticle was (2) magnetically active and (3) loaded with 
cisplatin. Reprinted from Reference 102. Copyright (2012) with permission from 
Elsevier. 
 
One of the great challenges with this approach is the practical generation of 
sufficient magnetic field gradients in confined locations in deep tissue. Additionally, 
overlaying tissue is unavoidably subjected to magnetic retention and the technique 
may be limited to tumors close to an accessible surface, e.g. skin, muscle, nasal, etc. 
or during surgery. However, some of these challenges are being addressed with 
optimized magnet designs, with a recent publication reporting the design of a Halbach 
array magnet for brain drug delivery applications with a useable depth of up to 50 
mm.107 A further consideration is the potential of cytotoxicity. SPIONs that are 
clinically approved for use have low or no toxicity at low levels, however at high 
exposure levels, or in their uncoated forms, cytotoxicity is seen.108 It will be vital to 
ensure the biological safety in their increasingly complex use. The safety of SPION 
agents has been reviewed previously in the literature, albeit not recently.109 
 
Electroporation and Electro-motive force 
Electroporation is the use of short electrical pulses to increase the permeability of 
cell membranes, by the formation of pores. Sufficiently high voltages cause 
unrecoverable pores to form in the cell, a process known as irreversible 
electroporation, which is typically fatal for the cell. Whilst this is currently under 
Page 20 of 75
ACS Paragon Plus Environment
ACS Nano
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
21 
 
investigation in clinical trials as a potential method of tumor ablation, reversible 
electroporation, where lower voltages cause only temporary poration, increase the 
cellular permeability to typically membrane impermeable drugs.110-114 The 
combination with chemotherapy, clinically termed electrochemotherapy (ECT), has 
been extensively used clinically to treat cutaneous or sub-cutaneous tumors, usually 
with bleomycin or cisplatin.115-118 ECT is a promising technique with a short 
treatment time, low side effects, and tumor response rates generally greater than 80% 
against a range of tumor types, but the technique is still limited to superficial tumors, 
is typically used for palliative management and requires the placement of two 
electrodes either side of the target site, which can be complicated depending upon the 
pathology. The clinical focus is now on targeting internal tumors,119,120 however as 
side effects include muscle contraction and pain, some areas will likely remain 
untreatable. Additionally some research is looking at the potential combination with 
nanoparticle formulations to improve targeting and guidance to a tumor before 
electroporation,121,122 although this has not been extended to the use of cisplatin yet. 
Alternatively, the application of a constant electric direct current causes 
iontophoresis; the movement of ions or charged molecules under an electric field. 
When electrodes are positioned on either side of a target tissue site, charged drugs 
will be forced into tissues and cells. Clinically, this is termed electro-motive drug 
administration (EMDA), and has been used in patients for dermal and intravesical, i.e. 
via the bladder, delivery of anti-cancer drugs.123-127 Iontophoresis is less disruptive 
than electroporation, although conversely treatment times are longer. Like 
electroporation, it is also capable of transporting nanoparticles into tissues, although 
again, the use has been primarily focused on dermal delivery, which benefits from 
non-invasive placement of electrodes. To the best of the authors’ knowledge, the use 
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of cisplatin loaded nanoparticles coupled with electroporation has not been reported in 
the literature. 
 
Ultrasound mediated delivery 
Ultrasound, a high frequency pressure wave well known for its clinical diagnostic 
use, has a number of therapeutic applications. For delivery purposes, the mechanical 
agitation and thermal effects of pressure waves upon tissue have been shown to 
increase both the uptake and extravasation of drugs in target tissues. Ultrasound-
mediated delivery (UMD) is an attractive option for cancer therapy due to its non-
invasiveness, site and depth specificity, low cost, short lived bioeffects and good in 
vivo safety profile. Several potential methods are responsible for the increase in 
nanoparticle uptake in a target area and are described in greater detail below. 
The propagating pressure wave of ultrasound generates a pressure gradient in the 
tissue due to the absorption of energy. This primary acoustic radiation force (ARF) is 
in the direction of ultrasound propagation and can be sufficient to cause a net 
displacement of tissue and particles in the focal region. ARF can cause loosening of 
endothelial junctions and tissues,128-132 reducing tumoral interstitial pressure, as well 
as increased permeability in deep tissue by heterogeneous motion of tissue.133-135 ARF 
can also cause movement of therapeutics directly into the target sites, a sonophoresis 
effect.131,136 These effects can lead to improved uptake and effect of free 
chemotherapeutics137-139 and nanoparticles in tumors,131, 140 but has not been used on 
cisplatin loaded nanoparticles. The transfer of momentum from the propagating wave 
to the surrounding fluid can also set up fluid flow within the tissue, known as acoustic 
streaming,141 which may also increase drug uptake.142  
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Just as SPION nanoparticles can act as theranostic agents for magnetic targeting 
applications, there are similar agents available capable of responding to externally 
applied ultrasound for both imaging and therapeutic purposes. These agents, 
described here as cavitation nuclei but divided broadly into microbubbles, 
nanodroplets and gas entraining particles, have significant vector capabilities and 
much research has gone into modifying these to improve drug and gene delivery.143-
145 The exact mechanism of action varies depending upon the agent, but broadly 
speaking, in the presence of an acoustic field, these agents undergo cavitation; the 
generation, oscillation and collapse of a gas/vapor bubble in a pressure field. The fluid 
motion and acoustic emissions produced by these oscillating and collapsing bubbles 
can increase local permeability by blood vessel rupture,146-149 disruption of cellular 
junctions and temporary poration of cell membranes.150,151 It has been demonstrated 
that microbubbles are susceptible to radiation forces and can be manipulated in vivo to 
ensure close proximity to the endothelial wall152,153 for improved endothelial 
rupture.154,155 This disruption increases permeability to co-delivered drugs and has 
been demonstrated to improve uptake and cytotoxicity to free cisplatin in target 
tumors in vivo.156-162  
A further attractive feature of cavitation nuclei is their potential for surface 
functionalisation. As permeability changes are temporary, it is essential that the drug 
and cavitation event are proximate. Cavitation nuclei typically consist of a gas bubble 
or phase change liquid encapsulated in a biocompatible shell, which can be surface 
functionalized to allow loading of drugs and/or nanoparticle drug carriers,163-165 as 
reviewed in several publications.166-168 For instance, microbubbles, an agent used both 
diagnostically and in therapeutic research, range in size from 1-10 µm, allowing 
considerable nanoparticle loading. Burke et al. demonstrated improved skeletal 
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muscle delivery in mice using fluorescent PLGA-based nanoparticles covalently 
attached to microbubbles compared to unbound co-injections of nanoparticle and 
microbubble,169 highlighting the importance of localizing drug and cavitation. 
Subsequently, this “composite-agent” loaded with fluorouracil was used to target 
gliomas in mice (See Figure 4).164 However, typical microbubbles have a short half-
life in circulation and are particularly lost during pulmonary passage. Some 
microbubbles are also particularly susceptible to Kupffer cell phagocytosis in the 
liver.170 The potential effect of this on the loaded drug clearance and off-site effects is 
not well understood.  
It should also be noted that although the components and concepts in nanoparticle 
loaded cavitation nuclei have been previously licensed for clinical purposes, the 
combination, and in particular the therapeutic use of cavitation nuclei, would almost 
certainly need to be demonstrated to be safe and significantly more effective than 
current approaches in extensive clinical trials. The consequence of this has already 
been seen in the choice of clinical trials that have been performed on the UMD 
concept. For instance, Dimcevski et al. examined the safety, toxicity and potential of 
improving gemcitabine delivery by UMD in 10 patients with inoperable pancreatic 
cancer.171 For this application, a clinical ultrasound machine and the diagnostic 
cavitation agent SonoVue® (Bracco Imaging Scandinavia AB, Oslo, Norway) were 
used. Although neither is designed for therapeutic purposes, these materials have been 
used safely and extensively for diagnostic imaging for decades. The positive outcome 
of the trial with an increase in median survival from 8.9 months with gemcitabine 
alone (from a historical study of 63 patients) to 17.6 months with the combination 
treatment, with no additional toxicity, does highlight the future potential of UMD. 
However, the therapeutically focused formulations of loaded cavitation nuclei 
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typically used in pre-clinical research will likely face substantial hurdles before 
clinical approval. 
 
 
Figure 4. Increased uptake of nanoparticles in gliomas treated with ultrasound (US) 
and a microbubble-nanoparticle composite agent (MNCA). a) Fluorescence-molecular 
tomography scans and b) fluorochrome analysis of ex vivo tissue demonstrate a 
significant uptake of the PLGA based nanoparticle in comparison to a co-injection of 
nanoparticles and microbubbles (MB + NP) or nanoparticle only (NP) controls. 
Reprinted from Reference 164.  Copyright (2014) with permission from Elsevier.  
 
Only one conference proceeding regarding the combined use of cavitation nuclei 
and encapsulated cisplatin could be found in the literature. Yang et al. presented work 
demonstrating a focused ultrasound treatment combined with microbubbles and a 
targeted liposome encapsulated cisplatin (Lipoplatin) could reduce tumor progression 
compared to untreated controls in glioblastoma rat brain model, with intact skull.172 
Whilst promising, it is difficult to determine the advantage of the treatment or the 
targeting due to a lack of appropriate controls and the effectiveness of the untargeted 
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Lipoplatin-only treatment. However, the authors’ previously published literature with 
doxorubicin loaded liposomes does suggest the ultrasound treatment is an effective 
addition.173  
Finally, high intensity, focused ultrasound (HIFU) is capable of producing 
significant temperature rises. As mentioned, acoustic energy is absorbed by tissue as 
the pressure wave propagates. Besides kinetic motion, energy is lost as heating of the 
tissue. When the acoustic wave is focused by a curved array or multiple elements, 
HIFU can lead to significant hyperthermia in a discrete region.174 Used primarily for 
clinical ablation, the highly localized nature of HIFU has seen a significant amount of 
research and trial use as a targeting and drug release technique, and will be covered in 
more detail in the section on thermal release. 
Ultrasound mediated delivery appears to be a potentially effective, non-invasive 
drug delivery technique capable of deep tissue targeting. However, there is still 
uncertainty regarding the mechanism by which acoustic energy or cavitation nuclei 
can improve delivery, and as such, the most appropriate choice regarding therapy. 
Additionally, although permeability has been reported up to 8 hours after ultrasound 
treatment,175 the typically short recovery times of tissue permeabilisation176,177 may 
indicate a need to focus on short-lived pharmaceuticals with poor target site uptake.  
Current work is also looking at overcoming the short lifespan of most cavitation 
agents in vivo,178,179 and potentially using submicron scale cavitation nuclei to 
extravasate into leaky tissues before activation. Finally, UMD cannot easily be 
applied in areas of overlying bone or gas. Bone is a strong absorber and scatterer of 
ultrasound, affecting both focusing and potentially causing unintended heating.83 In 
gas rich regions, ultrasound can be strongly reflected and may cause cavitation or 
mechanical damage to tissues at their tissue-gas interface.180 
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Lithotripsy 
Lithotripsy is a short-impulse pressure wave generated by extra-corporeal shock 
wave devices and is typically used for breakup of stones in kidneys and the gall 
bladder. The high energy shockwaves (HESW) generated are typically very short in 
duration (10 ns), have a low pulse repetition frequency and very high positive 
pressures. Lithotripsy devices are not commonly used for drug delivery in tumors, 
although some early attempts were made with free cisplatin,181,182 as the low 
frequencies and high pressures insonify large regions. Fine targeting of tumors is 
difficult183 and the uncontrolled nature can, in some cases, cause additional animal 
death184 and potential metastasis.185  
More recently, some work has looked at the potential combination of HESW and 
polymethyl methacrylate (PMMA) nanoparticles loaded with meso-tetrakis (4-
sulfonatophenyl) porphyrin (TPPS),186 a photosensitizer drug with high tumor affinity 
which generates reactive oxygen species when excited with light or ultrasound. 
Loading TPPS onto nanoparticles before HESW treatment resulted in a significant 
decrease in neuroblastoma cell proliferation in vitro. TPPS and HESW treatment 
without nanoparticles had no effect on cell proliferation. The rough surface of the 
nanoparticle was thought to act as a cavitation nuclei source for activating the drug 
and was also shown to improve the uptake of the drug into cells over 12 hours, 
although the mechanism for this was not described. Follow up work using radiotracer-
labelled drug in tumor bearing mice demonstrated increased uptake in spleen and liver 
versus free drug. HESW treatment also increased tumor uptake of the loaded drug, 
with associated growth reduction.187 Lithotripsy continues to find some application 
for sonodynamic therapy research,188,189 where ultrasound is required primarily for 
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drug activation rather than delivery, but is not a commonly used ultrasound-mediated 
delivery technique for chemotherapy, and no references could be found for the 
combination of HESW, cisplatin and nanoparticles. 
Targeted release 
Thermal release 
Whilst successfully targeting nanoparticles to tumors is in itself a challenge, it is 
compounded by the need to release the drug efficiently at the target site. Slow release 
of the drugs from nanoparticles is useful to avoid premature leakage, but can be a 
barrier to achieving effective release at the target site. As such, further methods have 
been tried to either use external methods or aspects of the intracellular tumor 
environment to improve release. 
As mentioned earlier, hyperthermia has been used to increase drug uptake in target 
tissues.190 Additionally, nanoparticles have been modified to improve their release 
kinetics under heating. Although not the topic for this review, thermosensitive 
liposomes (TSLs) loaded with cisplatin have been used to investigate potential 
delivery.191,192 TSLs are designed such that the lipids in the bilayer undergo phase 
transitions at sub-lethal temperatures (39-43oC) resulting in release of their payload. 
In their thesis, Landon describes the production of cisplatin loaded lipid TSLs for use 
in targeting xenograft or orthotopic rodent cancer models, with thermal energy 
provided by a water bath or specialized heating element, with a resulting increase in 
anti-tumor effect and reduced side effects versus free drug.193 TSLs have been 
recently reviewed in depth by Grüll & Langereis.194 
Submersion of targeted areas in heated water is a simple method to cause 
hyperthermia, however if accumulation in the target tumor is not guaranteed, this can 
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lead to off-site release. Instead, targeted techniques of heating have also been applied, 
much as has been done for hyperthermic delivery. Ultrasound is a modality capable of 
generating heat at target sites deep within tissue. By focusing the acoustic pressure 
wave generated by either a single curved transducer element, or multiple smaller 
elements, high energy absorption can be caused at the focal site, resulting in heating. 
Clinically, HIFU has been used for the targeted ablation of fibroids and is under 
investigation for non-invasive, thermal ablation of tumor tissue174, 195 combined with 
common chemotherapeutics;138, 176, 196-200 including cisplatin.201,202 
For nanocarriers, HIFU has been used to increase both delivery and release in a 
target tissue. Increased tumor uptake and drug distribution has been demonstrated 
with many TSLs,203-206 with one such agent, ThermoDox®, currently under 
investigation in a clinical trial (NCT02181075, 
https://clinicaltrials.gov/ct2/show/study/NCT02181075). Delivery of nanocarriers by 
HIFU hyperthermia is typically done using lower ultrasound intensities or reduced 
pulse durations, to maintain a mild hyperthermia rather than cause ablation, and has 
great translation potential as MRI guided HIFU machines are already clinically 
available and allow real-time, non-invasive thermometry and treatment.  
Besides TSL and standard liposomes, thermal HIFU has also been used in 
conjunction with nanoparticles. Oh et al. found increased delivery of docetaxel loaded 
pluronic nanoparticles in tumors using 0.8 MHz, 20 W/cm2 HIFU treatment at 10% 
duty cycle.80 This also correlated with increased apoptotic regions in tumors 
compared to an untreated control, however a hyperthermia only control was not 
performed. No temperature monitoring was performed in vivo, although the authors 
do state previous work at the chosen intensities lead to a 4-5oC temperature rise, and 
the higher intensities tested lead to thermal ablation. The authors, however, do state 
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that a mechanical ARF effect may also be responsible, as discussed previously for 
ultrasound based delivery strategies.  
Although HIFU is capable of non-invasive heating of an area deep within the body, 
the small focal area requires multiple transits of the ultrasound beam to achieve 
homogenous heating across a large target area. Additionally, the heating is not applied 
specifically to the nanocarrier, but to the tissue. An alternative approach is to modify 
the nanocarrier to respond to an external force directly. It has been demonstrated that 
magnetic nanoparticles can undergo significant heating in an alternating magnetic 
field (AMF). This can be used for tissue hypothermia to increase cisplatin 
uptake,207,208 or combined with drug loaded liposomes or solid nanoparticles to trigger 
drug release. This approach has been combined with cisplatin in a number of different 
nanocarrier formulations.209-212 
Other thermal approaches have included phototherapy and radiotherapy. Gold 
nanoparticles comprise an essential part of photothermal and chemotherapy 
approaches when combined with anticancer drugs, including cisplatin. For example, 
gold nanorods with a covalent cisplatin-polypeptide wrapping and folic acid 
conjugation were recently developed for the targeted photothermal and chemotherapy 
of highly aggressive triple negative breast cancer.213 The hybrid nanoparticles 
delivered systemically could significantly inhibit the growth of the tumor when 
combined with a near infrared laser illumination (See Figure 5). 
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Figure 5. Tumor growth after treatment in a triple negative breast cancer mouse 
model. Folate acid (FA) targeted gold nanorods (GNR) wrapped in biocompatible 
polypeptide poly(L-glutamic acid) (PGA), were loaded with cisplatin (Pt) and 
intravenously administered to animals. Laser irradiation (+ L) was applied to the 
tumor sites and tumors monitored over 22 days. Treated animals showed significant 
prevention in tumor growth versus controls to the point of complete elimination of 
tumor cells in the target region and no lung metastasis when examined by histology. 
Reproduced in part from Reference 213 with permission of The Royal Society of 
Chemistry. 
 
Carbon based nanostructures are also particularly effective at absorbing laser 
irradiation. DeWitt et al. report on the use of 100 nm single-walled carbon nanohorns 
conjugated to cisplatin, although the change in cellular uptake mechanisms for 
nanohorns at mild hyperthermia unfortunately resulted in a decrease of toxicity.214 An 
alternative photothermal approach using micelles loaded with a near-infrared cyanine 
dye and a Pt(IV)-prodrug resulted in complete ablation of both cisplatin-sensitive and 
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–resistant lung carcinomas in a mouse model.215 The penetration depth of laser light 
through tissue is always an issue for non-topical applications of phototherapy, 
however the technique can be easily paired with standard invasive procedures, such as 
endoscopies, catheters, etc. Intraoperative photodynamic therapy, where 
photosensitizers are administered and the relevant laser stimulation applied during 
surgery, is already in clinical trials for several tumor types that are difficult to fully 
resect.216,217 Additionally, photothermal near-infrared (NIR) absorbing nanoparticle 
formulations encapsulating cisplatin have been created, to overcome the limitation of 
poor tissue penetration of visible light.218,219 However, hyperthermia induced release 
of photosensitive drug loaded nanoparticles is still at the pre-clinical stage. 
 
Environmental sensitive release 
The tumor can present a unique environment in the body which can be exploited for 
triggered drug release and is the subject of a number of detailed reviews.220-222 As the 
focus of this review is primarily physical methods of delivery and release, these will 
only be briefly covered in this section.  
Due to the high glycolysis rate in cancer cells and poor waste removal in tumors, 
there is often a build-up of lactic acid in the tumor resulting in acidification of the 
environment. Additionally, the intracellular environment of tumor cells can be highly 
reductive, due to the increased presence of glutathione caused by high levels of 
glycolysis in the rapidly dividing cell.223 Constructing nanoparticles using redox 
sensitive, acid labile bonds, or pH sensitive materials can result in both better delivery 
of and release from nanoparticles in target sites.103, 224,225 In particular, Lin et al. have 
prepared redox sensitive Pt(IV) prodrugs as part of the structure of in silica coated 
metal-organic framework nanoparticles.226,227  
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Li et al. developed an interesting, multi-stage, polymeric, pH and redox sensitive 
cluster nanoparticle, dubbed an “iCluster”, to overcome certain barriers for cisplatin 
delivery.228 A reductive sensitive Pt(IV)-prodrug, an approach used in several 
cisplatin nanoparticle formulations,62, 229,230 was conjugated to ~5 nm nanoparticles, 
which in turn, self-assembled into ~100 nm nanoclusters. Li et al. demonstrated that 
at pH 6.8, the release of the 5 nm drug-loaded nanoparticles was significantly 
increased compared to the physiological pH 7.4. Additionally, the prodrug itself was 
only significantly released as cisplatin in a reductive environment, as would be found 
intracellularly, irrespective of pH. The “iCluster” loaded with Pt(IV)-prodrug showed 
significantly increased circulation time, penetration into tumors and cisplatin content 
in in vivo tumor models of pancreatic cancer, cisplatin-resistant lung cancer and 
highly invasive breast cancer, resulting in significantly improved tumor growth 
prevention and survival (See Figure 6). 
a)
 
 
Figure 6. a) Concept and mechanism of the “iCluster” nanoparticle. b) The 
construct effectively inhibited tumor growth in a drug-resistant human lung cancer 
mouse model. c) Survival was also improved in a metastatic triple negative breast 
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cancer mouse model. Adapted from Reference 228. Copyright (2016) with permission 
from PNAS. 
 
A further strategy is to use enzymatically degraded bonds. The inside of a cell 
contains many bioactive molecules which can degrade nanoparticles, to potentially 
allow the release of encapsulated drugs. This is an important consideration for 
nanoparticles taken up into lysosomal compartments within the cell. An interesting 
multi-drug construct based on polysaccharides was recently demonstrated by 
Deshpande and Jayakannan.231 Amphiphilic dextran molecules were synthesized to 
self-assemble into vesicles ranging from 160-210 nm in diameter with a hydrophilic 
core and hydrophobic shell. Succinic molecules attached to the dextran allowed 
conjugation of cisplatin to form its pro-drug. The amphiphilic nature of the dextran-
polymer vesicle also allowed loading of either water-soluble doxorubicin or water-
insoluble camptothecin or both. Dual and triple loaded polymeric vesicles showed a 
significant increase in release in the presence of esterases, as would be found in 
lysozymes, and also protected cisplatin from inactivation from glutathione. 
Ultimately, when compared to free drug, the single-, dual- and triple-loaded drugs 
showed significant in vitro cytotoxicity in a cisplatin resistant cell line, at lower drug 
concentrations, and in addition to strong additive or synergistic interactions between 
the drugs further reducing the required dose. One remaining concern is that these 
polysaccharide-based particles may not be cell type specific, and that further 
modification or techniques would be required to improve specificity to the target 
cancer. 
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Ultrasound triggered release 
Just as ultrasound can disrupt cellular membranes, it can also be used to release 
encapsulated drugs from loaded nanoparticles. Work by Schroeder et al., examined 
the release issues with SPI-77, an early liposomal formulation of cisplatin capable of 
long circulation and passive tumor uptake that ultimately failed in clinical trials due to 
the excellent stability of the liposome, resulting in negligible therapeutic benefit. 
Schroeder et al. demonstrated an increase in cisplatin release from liposomes in 
murine tumors treated by 20 kHz ultrasound, sometimes termed low frequency 
ultrasound (LFUS), from <3% in the untreated tumors, to almost 70% in treated 
tumors and an almost 3 fold rise in cisplatin present.232 This increase in local cisplatin 
concentration in a C26 footpad murine model, resulted in negligible growth of the 
tumor over 29 days in comparison to untreated controls. However, free cisplatin and 
the free cisplatin plus LFUS control also demonstrated a strong anti-proliferative 
effect, indicating the C26 cell line or applied dosage may not have been appropriate. 
The potential improvement in side effects was also not commented upon in the study. 
In their study, and follow-up modelling work on release rates,233 Enden and Schroeder 
determined the mechanism of release was primarily an increase in diffusion rather 
than liposome disintegration, rather than improved uptake into the tumor. On the basis 
of previous work, the authors suggest the mechanism of LFUS on liposomal release is 
transient pore-like defects due to the mechanical or cavitation effects at the surface of 
the liposome.234 
Similar effects were seen with TSLs and temperature insensitive liposomes (TILs) 
at higher ultrasound frequencies.  Oerlmans et al. used 1 MHz, continuous wave 
HIFU (CW-HIFU) or direct heating on TSLs and TILs loaded with encapsulated 
fluorescein.235 As expected, TSLs were sensitive to direct heating and CW-HIFU, 
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releasing 80% of their encapsulated fluorescein. Interestingly, TILs did not respond to 
the direct heating but significant release did occur with CW-HIFU. Oerlmans et al. 
further investigated using pulsed wave HIFU (PW-HIFU), a treatment regime that 
applies the same energy but over a longer period of time, and mostly eliminates 
hyperthermia. The TSLs and TILs underwent gradual increasing release of 
fluorescein, indicating a non-thermal method of release. Further experiments 
determined that cavitation was also not a factor in release, indicating a third method 
of ultrasound-triggered release.  As no significant changes in liposome size was seen 
during HIFU, only a temporary disruption of the liposome membrane occurred. The 
authors contend that collision of liposomes with the sample chamber walls, due to 
acoustic streaming, and the resulting shear forces, caused the reversible 
destabilization. Most intriguingly, this release was also demonstrated with a lipophilic 
dye in the liposome lipid membrane, which could not be released from the TSLs by 
direct heating, indicating a potential method of releasing lipophilic drugs from 
nanoparticles. However, the authors note that effective release during a non-thermal 
PW-HIFU regime, would require a much longer treatment time than is typically used 
for pre-clinical work, up to 30 minutes. Additionally, motion of liposomes and 
nanoparticles may be restricted in solid tumors.  
Besides liposomes, acoustically responsive nanoparticles have been trialed for 
targeted release of loaded therapeutics. Similar to the previous study on mechanical 
release from liposomes, Deckers et al. found that mPEG-b-p(HPMAm-Lacn) micelles 
would also undergo temporary destabilization under ultrasound exposure, an effect 
that was reduced with increased crosslinking between polymers and that was 
unrelated to any chemical changes of the polymer, thermal effects or cavitation. 
Instead, the effect was likely due to shears stress induced by micelle convection under 
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the acoustic radiation force within the sample chamber.236 Alternatively, Husseini et 
al., investigating acoustic release of doxorubicin from stabilized and unstabilized 
Pluronic P105 micelles, detected harmonic acoustic emissions during release, which 
can indicate the presence of cavitation. They ascribed the release phenomenon to the 
generation and collapse of bubbles in the solution, causing shear stress disruption of 
the micelles.237 The study was performed at low ultrasound frequencies (70 kHz), 
which is more capable of generating cavitation than the higher frequencies (1.5 MHz) 
used in the Deckers et al. study. Such low frequencies have excellent tissue 
penetration, but it may be more difficult to focus the cavitation effect to a specific 
area due to the wavelength resolution.  
Finally, solid mesoporous silica nanoparticles (MSNs) have also been shown to be 
capable of ultrasound based release after modifications.238,239 MSNs form as a series 
of open tubes, which allows convenient and efficient drug loading, but requires 
further modifications to trap the drug molecule within. Specialized polymers 
conjugated to the MSNs, called “gate keepers”, fulfil this role, by blocking the end of 
the tube and typically containing a labile bond (e.g. heat, acid, etc.) to allow triggered 
release. In a recent case, Paris et al. used an ultrasound-labile polymer to effectively 
cap the silica nanoparticle. In its native form, the polymer is hydrophobic, but after 
cleavage at the labile bond, become hydrophilic, effectively opening the MSN and 
allowing drug release.240 Paris et al. were able to demonstrate significant increase in 
the release of different fluorescent model drugs and doxorubicin from loaded MSNs 
when exposed to ultrasound (See Figure 7). Although it was demonstrated that the 
ultrasound caused a change in the chemical structure of the labile polymer that was 
essential for drug release, the ultrasound mechanism at work was not fully explored, 
which may be an issue if transferred to an in vivo situation.  
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Figure 7. LNCaP cells were incubated for 2 hours with rhodamine B labelled 
MSNs, loaded with fluorescein and capped with an ultrasound labile polymer, and 
either immediately fixed (top panel) or treated to 5 minutes ultrasound exposure 
before fixing (bottom panel). From left to right, cells were imaged under bright field 
with their nuclei stained with DAPI, for red fluorescence from the MSN, for green 
fluorescence from the fluorescein, and fluorescence channels were overlaid for the 
final image. In comparison to the untreated cells, ultrasound exposure has resulted in 
the release of fluorescein; as indicated by the green fluorescence throughout the cell 
cytoplasm and drop in co-localization between the MSNs and fluorescein. 
Reproduced from Reference 240. Copyright (2015) with permission of The American 
Chemical Society.   
 
Photorelease 
In addition to hyperthermia, novel strategies have been employed using photon 
absorption to trigger release of cisplatin. Li et al. manufactured a block polymer based 
nanoparticle encapsulating cisplatin and the photosensitive indocyanine green (ICG) 
dye.241 The block polymer was modified to contain a tellurium, which can bind to the 
platinum in cisplatin, but is rapidly oxidized by reactive oxygen species (ROS). Upon 
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stimulation with an 808 nm NIR laser, the ICG dye generates singlet oxygen which 
oxidizes the tellurium, causing release of the cisplatin. The initial nanocarrier 
complex is also highly stable, with less than 20% leakage of the cisplatin or ICG over 
120 hours, but releasing over 60% of the loaded cisplatin within 8 minutes of laser 
irradiation. When used in vivo on a xenograft breast cancer mouse model, 
significantly improved tumor regression was seen in comparison to free cisplatin and 
controls. In two of the five animals, no tumors were present after 26 days. 
Additionally, although tellurium is a mildly toxic metal, 5 days after treatment, 
negligible differences in biochemical organ function test and organ histology were 
seen between saline only control and the treated group. This was in stark comparison 
to the significant toxicity seen in the free cisplatin group. This approach highlights an 
interesting method to reduce cisplatin leakage from nanocarriers and specific release 
at potentially deep target sites due to NIR good tissue penetration. It should be noted 
though, that the animals treated with the loaded nanoparticle but without the laser 
irradiation, also demonstrated tumor growth control comparable to free cisplatin. The 
cause of this was not commented upon by the authors and may need further 
investigation in future. Additionally, 7 doses were supplied over the 26 days of 
treatment, followed 24 hours later by laser irradiation at the tumor site. This treatment 
regime may prove difficult to implement in the clinic, although this would likely be a 
minor concern. Finally, tellurium is one of the rarest metals on the planet, which 
could make this approach costly upon scaling up. 
A similar technique focusing on NIR as the release source, is to use rare earth metal 
lattices to form nanoparticles capable of “upconversion”. In simple terms, these 
lattices are capable of absorbing multiple photons of lower energy, i.e. NIR, and emit 
photons at higher energy, i.e. visible or ultraviolet light. This ability to create visible 
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or ultraviolet light deep within tissue, has allowed the nanoparticles combining 
photodynamic therapy and cisplatin to target deep tissue sites.242 In addition, the UV 
radiation emitted by these nanoparticles has been utilized to both release Pt(IV) 
prodrugs from UV-liable polymers243,244 and linked to the increased conversion of 
Pt(IV) prodrugs to active cisplatin in a polymer nanoparticle.245 
 
Concluding Remarks 
Platinum based drugs such as cisplatin offer a highly potent treatment for solid 
tumors, but to fully realize their potential several challenges still need to be addressed. 
Multiple nanoparticle formulations have been proposed and tested for cisplatin 
delivery. The combination of nanoparticle delivery with physical methods offers 
opportunities but also further challenges that may need to be reflected in the choice of 
formulation. For instance, should the agent be designed for rapid or sustained release? 
This in turn will affect the choice of delivery method, whether it relies upon thermal 
effects – e.g. the inclusion of thermosensitive linkages or polymers; magnetic 
targeting – e.g. the inclusion of magnetic material; cavitation nuclei – e.g. potential 
methods of attachment and issues of clearance with nuclei, or, acoustic radiation force 
– e.g. particle size for transit through the ECM.  
A topic not discussed in detail in this review is that of clinical approval. This review 
has focused on methods to improve the delivery and release of cisplatin loaded 
nanoparticles, however it should be noted that no nanoparticle or liposomal 
formulation of cisplatin has been approved for use at this time. Some of the 
challenges of nanoparticle design and approval are detailed in Anselmo and 
Mitragotri.246 In particular, cisplatin nanoparticles have typically demonstrated 
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lowered side effects and toxicity in clinical trials, but have rarely demonstrated a clear 
advantage over cisplatin alone. Additionally, the advent of other platinum based 
antineoplastic drugs, e.g. Carboplatin, Oxaliplatin, etc. has addressed some of the 
toxicity issues of cisplatin without the additional regulatory hurdles of nanoparticle 
agents. Many of the approaches detailed above may help the development of more 
effective cisplatin nanoparticles, but the lack of an approved formulation in clinical 
use may inhibit uptake by the pharmaceutical industry. 
Aspects of the tumor environment, such as the vascularity, the state of the 
supporting ECM, the presence of multiple cell types and heterogeneous cancer cell 
population, and the emerging role of immunological processes, all affect the 
deposition, delivery and effectiveness of a chosen therapeutic. In future, it is likely 
this choice will be driven by a more detailed characterization of a patient’s tumor, so 
called personalized medicine, and delivery mechanisms will undoubtedly form 
another factor in these important decisions.   
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